lymphocyte count predicted papillary RCC patients survival -
By Lynda Williams, Senior medwireNews Reporter
lymphopenia is an important predictor of outcome in patients undergoing surgery renal papillary carcinoma (PRCC), US researchers report.
team says that the absolute number of lymphocytes preoperatively (ALC), a systemic inflammatory response marker, has a similar prognostic power for the management of PRCC patients because it has for those with clear cell RCC .
"CLA may serve as useful complement already established prognosticators PRCC to help identify patients with clinically significant disease, which can benefit from enrollment in the neoadjuvant or adjuvant clinical trials, and provide indications adapt postoperative each patient monitoring schedules, "write Tahseen Al-Saleem, Fox Cancer Center-Temple Chase health system in Philadelphia, Pennsylvania, and colleagues.
This could also be true for patients with other types of cancer and lymphoma, they add in urologic oncology. initials seminars and surveys
CLA has been measured at least 3 months before the kidney resection in 192 patients and the cohort was followed for a median of 37.3 months.
CLA preoperative initial analysis as a continuous variable found the measure significantly associated with Node Metastasis tumors (TNM) stage and age. And when evaluated as a dichotomous variable, lymphopenia, which was defined as an ALC below 1300 cells / ul, was associated with higher TNM stage.
In addition, multivariate analysis showed that lymphopenia was a significant predictor of poor overall survival (hazard ratio = 2.28 vs ALC ≥1300 cells / ul) after adjustment for PRCC type, stage TNM, age, smoking and Charlson comorbidity index.
There was also a strong trend of poor cancer-specific survival for patients with lymphopenia; it may not have reached statistical significance due to the relatively small number of cancer deaths, comment the researchers.
However, the team concluded that large multicenter studies are needed to validate the impact of lymphopenia in patients with PRCC.
medwireNews licensed by permission of Springer Healthcare Ltd. © Springer Healthcare Ltd. All rights reserved. None of these parties endorse or recommend any commercial products, services or equipment.
EmoticonEmoticon